Health Care Equipment & Services

Fresenius’ 12‑August XETRA delisting, ISIN swap and capital‑adjustment signal a strategic shift to value‑based care, digital investment, and quality‑driven revenue growth.

Abbott Laboratories’ senior officer sells a few thousand shares under Rule 144, while a DCF valuation suggests shares may be trading above $94—what this means for investors.

Swiss markets dip as volatility spikes and earnings loom, with key companies like Givaudan and Lindt slipping while Alcon climbs—US CPI data set to sway investor sentiment.

Fresenius’s August 12 capital adjustment signals strategic readiness in German healthcare, boosting liquidity, digital adoption, and value‑based revenue.

Cardinal Health (CAH) gears up for next week’s earnings, offering insight into pharma logistics, supply‑chain resilience and inflation‑driven margins.

CVS Health expands into premium baby care with award‑winning Millie Moon, boosting margins and parent trust while integrating high‑quality diapers into its nationwide stores and online platform.

Coloplast’s new CEO Gavin Wood drives R&D and US marketing wins, as AB G Sundal Collier lifts the rating to hold—boosting growth prospects for urology, wound care and colorectal devices.

Alcon’s Q2 2026 results show revenue growth, strong margins, and new launches like UNITY and PanOptix Pro, driving higher 2026 guidance and shareholder value.

SEC filings reveal Mckesson Corp’s executive equity holdings and a 301‑share sale, showing transparent governance and long‑term incentive alignment for investors.

Adani Green Energy reports DOJ dismissed executive indictment with prejudice—no charges, no further action, and full compliance with SEBI rules, boosting investor confidence.